Compare Marathon Petroleum Corp (MPC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs BIO-TECHNE Corp — how do they compare? Marathon Petroleum Corp trades at $336.34 (market cap $89.95B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Marathon Petroleum Corp is far larger — about 8× BIO-TECHNE Corp's market cap, and Marathon Petroleum Corp pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| MPC | TECH | |
|---|---|---|
Market Cap | $89.95B | $11.24B |
Sector | Energy | Health |
52-Week High | $320.32 | $72.29 |
52-Week Low | $158.59 | $43.31 |
Enterprise Value | $116.48B | $11.32B |
Dividend Yield | 1.25% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $298.20, down 0.35% with a bearish technical signal despite strong fundamental performance. The stock shows exceptional earnings momentum with three consecutive quarterly beats, including a massive Q2 2026 EPS of $17.73 versus $14.27 expected. Valuation remains attractive with P/E of 10.34 and EV/EBITDA of 6.26, while maintaining robust profitability with 47.9% ROE.
MPC presents a compelling investment case with strong analyst support (76% buy ratings) and $330.70 price target upside. However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% pose fundamental concerns. Technical weakness near pivot point resistance at $297 requires monitoring despite positive refining margin outlook.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
